View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsSpectrum Pharmaceuticals 将来の成長Future 基準チェック /56現在、 Spectrum Pharmaceuticalsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報67.3%収益成長率75.36%EPS成長率Biotechs 収益成長23.9%収益成長率35.5%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日25 Jul 2023今後の成長に関する最新情報Breakeven Date Change • May 11Forecast breakeven date moved forward to 2024The 5 analysts covering Spectrum Pharmaceuticals previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 57% to 2023. The company is expected to make a profit of US$2.95m in 2024. Average annual earnings growth of 65% is required to achieve expected profit on schedule.お知らせ • Feb 01Spectrum Pharmaceuticals, Inc. Provides Sales Guidance for the Quarter Ended December 31, 2022Spectrum Pharmaceuticals, Inc. provided sales guidance for the quarter ended December 31, 2022. Preliminary net sales for the quarter ended December 31, 2022 is expected to be approximately $10 million.Breakeven Date Change • Dec 31Forecast to breakeven in 2025The 4 analysts covering Spectrum Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$26.8m in 2025. Average annual earnings growth of 57% is required to achieve expected profit on schedule.Breakeven Date Change • Sep 24No longer forecast to breakevenThe 5 analysts covering Spectrum Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$31.1m in 2024. New consensus forecast suggests the company will make a loss of US$12.3m in 2024.Breakeven Date Change • May 16Forecast to breakeven in 2024The 5 analysts covering Spectrum Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$46.6m in 2024. Average annual earnings growth of 65% is required to achieve expected profit on schedule.Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 5 analysts covering Spectrum Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$52.8m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesお知らせ • Aug 03Spectrum Pharmaceuticals, Inc.(NasdaqCM:SPPI) dropped from NASDAQ Composite IndexSpectrum Pharmaceuticals, Inc. has been dropped from Nasdaq Composite Index.お知らせ • May 18Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementSpectrum Pharmaceuticals, Inc. announced that on May 16, 2023, the Company received a written notification from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (Nasdaq) that the Company has regained compliance with the minimum bid price requirement set in Nasdaq Listing Rule 5550(a)(2). The Company previously received notification from the Staff on November 1, 2022, that its common stock failed to maintain a minimum bid price of $1.00 or more over the previous 30 consecutive business days, as required by the Nasdaq Listing Rules. Since then, the Staff has determined that for the 10 consecutive business days from May 2 to May 15, 2023, the closing bid price of Spectrum’s common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed.Breakeven Date Change • May 11Forecast breakeven date moved forward to 2024The 5 analysts covering Spectrum Pharmaceuticals previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 57% to 2023. The company is expected to make a profit of US$2.95m in 2024. Average annual earnings growth of 65% is required to achieve expected profit on schedule.お知らせ • Feb 09Spectrum Pharmaceuticals, Inc. Receives Permanent J-Code for ROLVEDON Injection (J1449) from U.S. Centers for Medicare & Medicaid ServicesSpectrum Pharmaceuticals, Inc. announced that a permanent J-code, J1449, has been issued for ROLVEDON (eflapegrastim-xnst) Injection by the U.S. Centers for Medicare & Medicaid Services (CMS) effective as of April 1, 2023. J-codes are permanent reimbursement codes used by commercial insurance plans, Medicare, Medicare Advantage, and other government payers for Medicare Part B drugs like ROLVEDON that are administered by a physician. Claims submission and documentation are simplified with a permanent J-code, facilitating and streamlining the billing and reimbursement process. The permanent J-code for ROLVEDON, J1449 (Injection, eflapegrastim-xnst, 0.1 mg), will take effect April 1, 2023.お知らせ • Feb 01Spectrum Pharmaceuticals, Inc. Provides Sales Guidance for the Quarter Ended December 31, 2022Spectrum Pharmaceuticals, Inc. provided sales guidance for the quarter ended December 31, 2022. Preliminary net sales for the quarter ended December 31, 2022 is expected to be approximately $10 million.お知らせ • Jan 05Spectrum Pharmaceuticals Announces Executive ChangesSpectrum Pharmaceuticals, Inc. announced that Francois J. Lebel, M.D., Executive Vice President and Chief Medical Officer, will step down from his role to pursue other opportunities, effective immediately. The company’s clinical development function will be led by Dr. Shanta Chawla, Vice President, Clinical Development, also effective immediately. Dr. Chawla was the principal physician on the ROLVEDON™ (eflapegrastim-xnst) injection Phase 3 program and was instrumental in successfully navigating the BLA submission that resulted in the drug’s approval. Dr. Lebel will serve as a consultant to Spectrum through March 2023 to facilitate a seamless transition.Breakeven Date Change • Dec 31Forecast to breakeven in 2025The 4 analysts covering Spectrum Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$26.8m in 2025. Average annual earnings growth of 57% is required to achieve expected profit on schedule.Breakeven Date Change • Sep 24No longer forecast to breakevenThe 5 analysts covering Spectrum Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$31.1m in 2024. New consensus forecast suggests the company will make a loss of US$12.3m in 2024.Breakeven Date Change • May 16Forecast to breakeven in 2024The 5 analysts covering Spectrum Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$46.6m in 2024. Average annual earnings growth of 65% is required to achieve expected profit on schedule.Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 5 analysts covering Spectrum Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$52.8m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Breakeven Date Change • Aug 07No longer forecast to breakevenThe 6 analysts covering Spectrum Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$4.50m in 2023. New consensus forecast suggests the company will make a loss of US$21.5m in 2023.Board Change • Jul 31High number of new directorsIndependent Director Nora Brennan was the last director to join the board, commencing their role in 2020.Breakeven Date Change • May 19Forecast breakeven pushed back to 2024The 6 analysts covering Spectrum Pharmaceuticals previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of US$79.4m in 2024. Average annual earnings growth of 68% is required to achieve expected profit on schedule.Is New 90 Day High Low • Mar 05New 90-day low: €2.64The company is down 34% from its price of €4.02 on 04 December 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €13.33 per share.Is New 90 Day High Low • Dec 31New 90-day low: €2.78The company is down 21% from its price of €3.50 on 02 October 2020. The German market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €10.83 per share.Is New 90 Day High Low • Dec 15New 90-day high: €4.04The company is up 15% from its price of €3.52 on 16 September 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.15 per share.Is New 90 Day High Low • Nov 10New 90-day low: €2.84The company is down 13% from its price of €3.28 on 11 August 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Biotechs industry, which is also down 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.99 per share.Is New 90 Day High Low • Sep 19New 90-day high: €3.84The company is up 39% from its price of €2.76 on 19 June 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €28.74 per share.業績と収益の成長予測DB:NTR - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20252019736141412/31/2024127141836512/31/202373-18-21233/31/202326-68-88-88N/A12/31/202210-78-97-97N/A9/30/2022N/A-106-102-102N/A6/30/2022N/A-117-109-109N/A3/31/2022N/A-138-115-115N/A12/31/2021N/A-158-120-119N/A9/30/2021N/A-169-121-122N/A6/30/2021N/A-184-127-125N/A3/31/2021N/A-166-127-123N/A12/31/2020N/A-171-127-122N/A9/30/2020N/A-162-127-120N/A6/30/2020N/A-140-131-119N/A3/31/2020N/A-136-138-128N/A12/31/2019N/A-135-144-135N/A9/30/2019N/A-148-127-116N/A6/30/2019N/A-191-103-100N/A3/31/2019N/A-147-79-76N/A12/31/2018N/A-127-65-62N/A9/30/201829-102-63-63N/A6/30/201865-51-59-59N/A3/31/201899-87-46-45N/A12/31/2017N/A-101-39-39N/A9/30/2017135-81-30-29N/A6/30/2017132-81-36-36N/A3/31/2017132-84-54-54N/A12/31/2016146-70N/A-40N/A9/30/2016162-55N/A-34N/A6/30/2016157-56N/A-30N/A3/31/2016168-35N/A5N/A12/31/2015163-53N/A7N/A9/30/2015164-50N/A15N/A6/30/2015183-42N/A34N/A3/31/2015185-44N/A31N/A12/31/2014187-46N/A-4N/A9/30/2014176-82N/A-7N/A6/30/2014171-78N/A-30N/A3/31/2014157-84N/A-64N/A12/31/2013156-62N/A-2N/A9/30/2013184-15N/A-2N/A6/30/201321114N/A30N/A3/31/201324742N/A67N/A12/31/201226894N/A72N/A9/30/201225195N/A75N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: NTRは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 0.2% ) よりも高い成長率であると考えられます。収益対市場: NTR今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: NTR今後 3 年以内に収益を上げることが予想されます。収益対市場: NTRの収益 ( 35.5% ) German市場 ( 6.7% ) よりも速いペースで成長すると予測されています。高い収益成長: NTRの収益 ( 35.5% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: NTRの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/08/01 13:19終値2023/07/31 00:00収益2023/03/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Spectrum Pharmaceuticals, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関David BuckB. Riley Securities, Inc.Alethia YoungCantor Fitzgerald & Co.Reni BenjaminCitizens JMP Securities, LLC6 その他のアナリストを表示
Breakeven Date Change • May 11Forecast breakeven date moved forward to 2024The 5 analysts covering Spectrum Pharmaceuticals previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 57% to 2023. The company is expected to make a profit of US$2.95m in 2024. Average annual earnings growth of 65% is required to achieve expected profit on schedule.
お知らせ • Feb 01Spectrum Pharmaceuticals, Inc. Provides Sales Guidance for the Quarter Ended December 31, 2022Spectrum Pharmaceuticals, Inc. provided sales guidance for the quarter ended December 31, 2022. Preliminary net sales for the quarter ended December 31, 2022 is expected to be approximately $10 million.
Breakeven Date Change • Dec 31Forecast to breakeven in 2025The 4 analysts covering Spectrum Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$26.8m in 2025. Average annual earnings growth of 57% is required to achieve expected profit on schedule.
Breakeven Date Change • Sep 24No longer forecast to breakevenThe 5 analysts covering Spectrum Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$31.1m in 2024. New consensus forecast suggests the company will make a loss of US$12.3m in 2024.
Breakeven Date Change • May 16Forecast to breakeven in 2024The 5 analysts covering Spectrum Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$46.6m in 2024. Average annual earnings growth of 65% is required to achieve expected profit on schedule.
Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 5 analysts covering Spectrum Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$52.8m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
お知らせ • Aug 03Spectrum Pharmaceuticals, Inc.(NasdaqCM:SPPI) dropped from NASDAQ Composite IndexSpectrum Pharmaceuticals, Inc. has been dropped from Nasdaq Composite Index.
お知らせ • May 18Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementSpectrum Pharmaceuticals, Inc. announced that on May 16, 2023, the Company received a written notification from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (Nasdaq) that the Company has regained compliance with the minimum bid price requirement set in Nasdaq Listing Rule 5550(a)(2). The Company previously received notification from the Staff on November 1, 2022, that its common stock failed to maintain a minimum bid price of $1.00 or more over the previous 30 consecutive business days, as required by the Nasdaq Listing Rules. Since then, the Staff has determined that for the 10 consecutive business days from May 2 to May 15, 2023, the closing bid price of Spectrum’s common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed.
Breakeven Date Change • May 11Forecast breakeven date moved forward to 2024The 5 analysts covering Spectrum Pharmaceuticals previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 57% to 2023. The company is expected to make a profit of US$2.95m in 2024. Average annual earnings growth of 65% is required to achieve expected profit on schedule.
お知らせ • Feb 09Spectrum Pharmaceuticals, Inc. Receives Permanent J-Code for ROLVEDON Injection (J1449) from U.S. Centers for Medicare & Medicaid ServicesSpectrum Pharmaceuticals, Inc. announced that a permanent J-code, J1449, has been issued for ROLVEDON (eflapegrastim-xnst) Injection by the U.S. Centers for Medicare & Medicaid Services (CMS) effective as of April 1, 2023. J-codes are permanent reimbursement codes used by commercial insurance plans, Medicare, Medicare Advantage, and other government payers for Medicare Part B drugs like ROLVEDON that are administered by a physician. Claims submission and documentation are simplified with a permanent J-code, facilitating and streamlining the billing and reimbursement process. The permanent J-code for ROLVEDON, J1449 (Injection, eflapegrastim-xnst, 0.1 mg), will take effect April 1, 2023.
お知らせ • Feb 01Spectrum Pharmaceuticals, Inc. Provides Sales Guidance for the Quarter Ended December 31, 2022Spectrum Pharmaceuticals, Inc. provided sales guidance for the quarter ended December 31, 2022. Preliminary net sales for the quarter ended December 31, 2022 is expected to be approximately $10 million.
お知らせ • Jan 05Spectrum Pharmaceuticals Announces Executive ChangesSpectrum Pharmaceuticals, Inc. announced that Francois J. Lebel, M.D., Executive Vice President and Chief Medical Officer, will step down from his role to pursue other opportunities, effective immediately. The company’s clinical development function will be led by Dr. Shanta Chawla, Vice President, Clinical Development, also effective immediately. Dr. Chawla was the principal physician on the ROLVEDON™ (eflapegrastim-xnst) injection Phase 3 program and was instrumental in successfully navigating the BLA submission that resulted in the drug’s approval. Dr. Lebel will serve as a consultant to Spectrum through March 2023 to facilitate a seamless transition.
Breakeven Date Change • Dec 31Forecast to breakeven in 2025The 4 analysts covering Spectrum Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$26.8m in 2025. Average annual earnings growth of 57% is required to achieve expected profit on schedule.
Breakeven Date Change • Sep 24No longer forecast to breakevenThe 5 analysts covering Spectrum Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$31.1m in 2024. New consensus forecast suggests the company will make a loss of US$12.3m in 2024.
Breakeven Date Change • May 16Forecast to breakeven in 2024The 5 analysts covering Spectrum Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$46.6m in 2024. Average annual earnings growth of 65% is required to achieve expected profit on schedule.
Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 5 analysts covering Spectrum Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$52.8m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Breakeven Date Change • Aug 07No longer forecast to breakevenThe 6 analysts covering Spectrum Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$4.50m in 2023. New consensus forecast suggests the company will make a loss of US$21.5m in 2023.
Board Change • Jul 31High number of new directorsIndependent Director Nora Brennan was the last director to join the board, commencing their role in 2020.
Breakeven Date Change • May 19Forecast breakeven pushed back to 2024The 6 analysts covering Spectrum Pharmaceuticals previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of US$79.4m in 2024. Average annual earnings growth of 68% is required to achieve expected profit on schedule.
Is New 90 Day High Low • Mar 05New 90-day low: €2.64The company is down 34% from its price of €4.02 on 04 December 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €13.33 per share.
Is New 90 Day High Low • Dec 31New 90-day low: €2.78The company is down 21% from its price of €3.50 on 02 October 2020. The German market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €10.83 per share.
Is New 90 Day High Low • Dec 15New 90-day high: €4.04The company is up 15% from its price of €3.52 on 16 September 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.15 per share.
Is New 90 Day High Low • Nov 10New 90-day low: €2.84The company is down 13% from its price of €3.28 on 11 August 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Biotechs industry, which is also down 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.99 per share.
Is New 90 Day High Low • Sep 19New 90-day high: €3.84The company is up 39% from its price of €2.76 on 19 June 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €28.74 per share.